Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Teva Pharmaceutical Industries Ltd patents


Recent patent applications related to Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd is listed as an Agent/Assignee. Note: Teva Pharmaceutical Industries Ltd may have other listings under different names/spellings. We're not affiliated with Teva Pharmaceutical Industries Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Teva Pharmaceutical Industries Ltd-related inventors


Method of determining the molecular weight distribution of glatiramer acetate using multi-angle laser light scattering (malls)

The present invention provides a process for characterizing a glatiramer acetate, related drug substance (gards) or a glatiramer acetate related drug product (gardp) comprising separating a batch of a gards or gardp according to hydrophobicity and determining the molar mass of the separated material, thereby characterizing the gards or gardp by molar mass as a function of hydrophobicity.. . ... Teva Pharmaceutical Industries Ltd

Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., huntington's disease (hd), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., hd. ... Teva Pharmaceutical Industries Ltd

Treatment of multiple sclerosis with combination of laquinimod and a statin

This invention provides a method of treating a subject afflicted with multiple sclerosis (ms) or presenting a clinically isolated syndrome (cis) comprising administering to the subject laquinimod as an add-on to or in combination with a statin. This invention also provides a package and a pharmaceutical composition comprising laquinimod and a statin for treating a subject afflicted with ms or presenting cis. ... Teva Pharmaceutical Industries Ltd

Treatment of crohn's disease with delayed-release 6-mercaptopurine

Methods of treating patients suffering from crohn's disease or ulcerative colitis who did not experience a clinical response to previous thiopurine administration, or suffered side effects from previous thiopurine administration, by administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed. Methods of treating patients suffering from crohn's disease or ulcerative colitis who are also being administered a steroid, 5-aminosalicylic acid, or an antibiotic by adjunctively administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are also disclosed.. ... Teva Pharmaceutical Industries Ltd

Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod

This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. ... Teva Pharmaceutical Industries Ltd

Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., huntington's disease (hd), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., hd. ... Teva Pharmaceutical Industries Ltd

Pharmaceutical compositions of memantine

The present invention relates to oral dosage forms comprising memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.. . ... Teva Pharmaceutical Industries Ltd

Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod

This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. ... Teva Pharmaceutical Industries Ltd

Devices and methods for preparing gastroretentive dosage forms

The present disclosure provides a device for self-preparation of a gastroretentive dosage form being capable of transitioning between a collapsed configuration and an expanded configuration, the device comprising an assembly unit including: a compartment configured for accommodating the gastroretentive dosage form in the expanded configuration; and a mechanical system configured for, upon operation of an actuation mechanism: (a) transitioning said gastroretentive dosage form into the collapsed configuration; and (b) locking said collapsed gastroretentive dosage form into the collapsed configuration; wherein the device is configured for being portable.. . ... Teva Pharmaceutical Industries Ltd

Transmucosal delivery of laquinimod by oral patches

The subject invention provides an oral patch comprising: a) a liner; and b) a film composition thereon, the film composition comprising (i) laquinimod in an amount of about 0.1%-20% by weight of the film composition, and (ii) one or more film forming agents in a total amount of about 40%-90% by weight of the film composition. The subject invention also provides a method for delivering laquinimod across the oral mucosa of a subject, or for treating a human subject afflicted with a form of multiple sclerosis, comprising periodically administering to the human subject an oral patch as described herein. ... Teva Pharmaceutical Industries Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Teva Pharmaceutical Industries Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Teva Pharmaceutical Industries Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###